WVT078(一种BCMA×CD3双特异性抗体)的临床前发现与初步临床数据
WVT078是一种靶向BCMA和CD3的双特异性抗体,临床前模型显示其具有强效T细胞激活和抗多发性骨髓瘤活性,在食蟹猴中耐受性良好。正在进行的首次人体I期剂量递增研究(NCT04123418)中,33例患者接受每周一次静脉WVT078治疗,在已测试的48-250 µg/kg活性剂量组(n=26)中,总缓解率为38.5%(90% CI: 22.6-56.4%),完全缓解率为11.5%(90% CI: 3.2-27.2%)。最高测试剂量组总缓解率为75%(4例中3例)。安全性方面,26例(78.8%)患者报告至少1例≥3级不良事件,其中16例事件怀疑与药物相关;20例(60.6%)发生细胞因子释放综合征。
要点
- WVT078在临床前模型中显示强效T细胞激活和抗骨髓瘤活性,食蟹猴耐受性良好。
- I期剂量递增研究中,48-250 µg/kg剂量组(n=26)总缓解率38.5%(90% CI: 22.6-56.4%)。
- 最高测试剂量组总缓解率75%(4例中3例),≥3级不良事件发生率78.8%,细胞因子释放综合征发生率60.6%。
核心结论
- WVT078在已测试剂量下具有可接受的安全性特征,并显示出初步临床活性证据。
研究设计与样本
- 正在进行的首次人体I期剂量递增研究(NCT04123418),33例患者接受每周一次静脉WVT078治疗。
主要发现
- 在已测试的48-250 µg/kg活性剂量组(n=26)中,总缓解率为38.5%(90% CI: 22.6-56.4%),完全缓解率(严格完全缓解+完全缓解)为11.5%(90% CI: 3.2-27.2%)。
- 在最高测试剂量组中,总缓解率为75%(4例中3例)。
- 26例(78.8%)患者报告至少1例≥3级不良事件,其中16例事件怀疑与药物相关。
- 20例(60.6%)患者发生细胞因子释放综合征。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
B-cell maturation antigen (BCMA) is an ideal target in multiple myeloma (MM) due to highly specific expression in malignant plasma cells. BCMA-directed therapies including antibody drug conjugates, chimeric antigen receptor-T cells and bispecific antibodies (BsAbs) have shown high response rates in MM. WVT078 is an anti-BCMA× anti-CD3 BsAb that binds to BCMA with subnanomolar-affinity. It was selected based on potent T cell activation and anti-MM activity in preclinical models with favorable tolerability in cynomolgus monkey. In the ongoing first-in-human phase I dose-escalation study (NCT04123418), 33 patients received intravenous WVT078 once weekly at escalated dosing. At the active doses of 48-250 µg/kg tested to date (n = 26), the overall response rate (ORR) was 38.5% (90% CI: 22.6-56.4%) and the complete response rate (CRR, stringent complete response + complete response) was 11.5%, (90% CI: 3.2-27.2%). At the highest dose level tested, the ORR was 75% (3 of 4 patients). 26 (78.8%) patients reported at least one Grade ≥3 AE and 16 of these AEs were suspected to be drug related. 20 patients (60.6%) experienced cytokine release syndrome. WVT078 has an acceptable safety profile and shows preliminary evidence of clinical activity at doses tested to date.
引用
- Raab MS, Cohen YC, Schjesvold F, et al. Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody. Leukemia. 2023. PMID: 37024520. doi:10.1038/s41375-023-01883-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。